NCT01814839View on ClinicalTrials.gov

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
TTR-mediated Amyloidosis
Interventions
DRUG

ALN-TTRSC (revusiran)

Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (2)

LS2 9LH

Clinical Site, Leeds

NW10 7EW

Clinical Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY